AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$HIMS

What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call

Hims & Hers Health (HIMS) reported Q3 earnings, announcing plans to expand its weight-loss offerings and defer $18M in revenue. International revenue grew to $233M, with Eucalyptus contributing $135M. Gross margin fell to 57% due to lower-margin products. The company raised its 2026 international revenue outlook to $650M. Q4 revenue is forecasted between $875M and $895M, with adjusted EBITDA between $70M and $90M.

Original reporting
finance.yahoo.com
Published Nov 10, 2026, 5:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 5:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Hims & Hers Health (HIMS) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The earnings beat on revenue but miss on margin and lowered guidance likely triggers a sell‑off.

02

Market read

Earnings and guidance update for a mid‑cap telehealth firm; actionable for traders monitoring health‑tech stocks.

03

What to watch

AI‑driven platform usage could improve efficiency; upcoming product launches (BPC‑157, TB‑500) may boost future growth.

Relevance 8/10Novelty 8/10Timing: post-earnings today

Background

Hims & Hers Health reported Q3 results, highlighting international growth, margin compression, and revised 2026 guidance.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Q3 earnings release with revenue, margin, EBITDA numbers and lowered 2026 guidance.

Expected impact

likely pressure as market prices in lower EBITDA guidance and margin decline

Evidence & confidence

Adjusted EBITDA guidance reduced; gross margin fell 7 pts; revenue outlook tightened, which typically depresses stock price.

Market effects

Sector

Weight‑loss and telehealth segments may see broader scrutiny as margins compress.

Regional

International revenue outlook raised, but margin pressure could temper European investor sentiment.

Global

Limited to HIMS and its niche telehealth market.

Counterpoint

What could challenge this read

Despite guidance cuts, cash position remains strong; potential upside if new weight‑loss products gain traction.

Key entities

  • company
    Hims & Hers Health

    Telehealth provider (NYSE:HIMS) reporting Q3 earnings.

Read at source← All news

StoryHims & Hers posts 49% revenue growth but margin collapse and cuts 2026 guidance

Also covered by

5 outlets

Related articles

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com
$HIMSHighAI 8/10

Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth

Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.

finance.yahoo.com